Critical Contrast: Ekso Bionics Holdings (EKSO) versus Unilife Corp (UNIS)
Ekso Bionics Holdings (NASDAQ: EKSO) and Unilife Corp (NASDAQ:UNIS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Valuation & Earnings
This table compares Ekso Bionics Holdings and Unilife Corp’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ekso Bionics Holdings||$7.49 million||3.86||-$27.14 million||($1.55)||-0.72|
Unilife Corp has higher revenue, but lower earnings than Ekso Bionics Holdings.
Institutional and Insider Ownership
6.0% of Ekso Bionics Holdings shares are held by institutional investors. Comparatively, 14.9% of Unilife Corp shares are held by institutional investors. 7.1% of Ekso Bionics Holdings shares are held by company insiders. Comparatively, 1.9% of Unilife Corp shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Ekso Bionics Holdings and Unilife Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ekso Bionics Holdings||-372.20%||-798.93%||-146.30%|
This is a summary of current ratings for Ekso Bionics Holdings and Unilife Corp, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ekso Bionics Holdings||0||0||2||0||3.00|
Ekso Bionics Holdings presently has a consensus target price of $6.00, indicating a potential upside of 435.71%. Given Ekso Bionics Holdings’ higher possible upside, equities research analysts clearly believe Ekso Bionics Holdings is more favorable than Unilife Corp.
Risk & Volatility
Ekso Bionics Holdings has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500. Comparatively, Unilife Corp has a beta of -0.92, suggesting that its stock price is 192% less volatile than the S&P 500.
Ekso Bionics Holdings beats Unilife Corp on 6 of the 9 factors compared between the two stocks.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The companys Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.
Unilife Corp Company Profile
Unilife Corp is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.